🇺🇸 DETRUSITOL in United States

432 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fall — 68 reports (15.74%)
  2. Urinary Tract Infection — 55 reports (12.73%)
  3. Urinary Retention — 48 reports (11.11%)
  4. Death — 40 reports (9.26%)
  5. Drug Ineffective — 40 reports (9.26%)
  6. Fatigue — 40 reports (9.26%)
  7. Hypertension — 36 reports (8.33%)
  8. Dizziness — 35 reports (8.1%)
  9. Dry Mouth — 35 reports (8.1%)
  10. Nausea — 35 reports (8.1%)

Source database →

DETRUSITOL in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is DETRUSITOL approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for DETRUSITOL in United States?

Rambam Health Care Campus is the originator. The local marketing authorisation holder may differ — check the official source linked above.